Glutathione Side Effects: What Studies Report

What the published literature covers, and what it does not

Research on glutathione and the skin clusters around three routes of administration: oral supplementation, topical application (sometimes paired with a delivery procedure such as microneedling), and injectable use, which reviews have characterised as largely off-label for cosmetic purposes. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or product. It summarises what researchers measured and reported, and it is equally explicit about the questions the peer-reviewed record does not answer.

That distinction matters for adverse events. A trial that enrolled healthy volunteers for twelve weeks can report on tolerability over twelve weeks in healthy volunteers, and nothing more. Several frequently asked practical questions — handling temperature, post-reconstitution stability windows, injection route comparisons, reflux and bowel symptoms, and concurrent use with prescription topicals — were not study endpoints in the papers cited below. Where that is the case, this page says so rather than filling the gap.

Oral Glutathione: What Studies Report

The most frequently cited controlled trial randomised 60 healthy participants to oral glutathione or oxidised glutathione at 250 mg per day or placebo for 12 weeks and reported reductions in melanin index at several sites along with improvement in skin elasticity and wrinkle measures, with no serious adverse effects observed over that period (PMID 28490897). A systematic review of the clinical effect of glutathione on skin colour and related skin conditions pooled studies across oral, topical and injectable routes and reported that adverse-event reporting was inconsistent and often incomplete across the included trials (PMID 30895708).

A 2025 narrative review examining the safety and efficacy of glutathione supplementation for skin lightening reported that the available human safety data came predominantly from small, short-duration studies and that long-term supplementation had not been characterised (PMID 40013212). A 2025 systematic review of glutathione as a skin-lightening agent and in melasma similarly reported that oral and topical formulations accounted for most of the usable evidence, while the intravenous literature remained weak (PMID 39444151).

Injectable Glutathione: What Reviews Report

Reviews of glutathione as a skin-whitening agent examined the facts, myths and controversies surrounding parenteral use and reported that intravenous administration for cosmetic lightening was not supported by controlled evidence and had attracted regulatory advisories (PMID 27088927). A companion review asking whether glutathione for skin lightening was a "regnant myth or evidence-based verity" reported that efficacy claims outran the published data and that injectable use in particular lacked systematic safety surveillance (PMID 29445569). The 2025 narrative review reached a similar conclusion, reporting that safety assessment of injectable glutathione remained inadequate for clinical recommendation (PMID 40013212).

Subcutaneous versus intramuscular administration

None of the reviews or trials summarised here compared subcutaneous with intramuscular glutathione injection, and none reported pharmacokinetic or tolerability differences between those two routes. The injectable literature discussed in the reviews centred on intravenous cosmetic use, which researchers described as off-label and poorly evidenced (PMID 27088927, PMID 29445569). In other words, the frequently asked subcutaneous-versus-intramuscular question has no answer in this body of work; the absence of comparative data is itself the finding.

Gastrointestinal Questions — Reflux and Constipation: What Studies Report

Reflux and constipation were not prespecified endpoints in the dermatology studies reviewed here. The 12-week randomised oral trial reported no serious adverse effects among its healthy participants, but it did not publish a symptom-by-symptom gastrointestinal breakdown at that dose and duration (PMID 28490897). The systematic review of clinical glutathione studies reported that adverse-event capture was inconsistent across trials, which means mild or self-limited digestive complaints could plausibly have gone unrecorded (PMID 30895708).

Equally, no trial in this set tested glutathione as a treatment for gastro-oesophageal reflux, and the narrative and systematic reviews confined their scope to pigmentation and skin outcomes rather than gastrointestinal disease (PMID 40013212, PMID 39444151). Readers encountering claims in either direction — that glutathione causes reflux, or relieves it — should recognise that the dermatology evidence base was never designed to test either proposition.

Combination With Azelaic Acid or Tretinoin: What Studies Report

The verified literature contains no trial pairing glutathione with azelaic acid, and none pairing it with tretinoin. The closest published work combined topical glutathione with a physical delivery method rather than another active: an evaluator-blind, split-face pilot trial compared carboxytherapy against combined microneedling with topical glutathione in patients with periorbital hyperpigmentation and reported outcomes for both approaches in a small sample (PMID 36865870). A systematic review of antioxidants in melasma surveyed agents including glutathione and reported substantial heterogeneity in formulations, concentrations and comparators across the included studies (PMID 40487500).

Because no head-to-head or additive-combination data exist in this set, questions about irritation, tolerability or interaction when glutathione is layered with a prescription retinoid or with azelaic acid cannot be answered from the published record. Reviews of the pigmentation literature reported that standardisation of topical glutathione vehicles and concentrations was itself an unresolved problem (PMID 39444151).

Storage, Refrigeration and Reconstitution: What the Literature Describes

Handling and stability are pharmaceutical questions, and the dermatology studies cited on this page did not measure them. None of the trials or reviews summarised here reported storage temperatures, cold-chain requirements, room-temperature excursion limits, powder shelf life, or post-reconstitution stability windows for glutathione preparations (PMID 30895708, PMID 40013212). Such parameters are product-specific and formulation-specific: they appear in manufacturer labelling, certificates of analysis, pharmacopoeial monographs and, for compounded preparations, in the compounding standards that govern beyond-use dating. Research-use-only materials carry no clinical labelling at all.

Does glutathione need to be refrigerated, and for how long does it last?

The published clinical and review literature indexed here is silent on refrigeration, on how long a vial or powder remains within specification in a refrigerator, and on how long it may sit outside one. Reviews focused instead on efficacy endpoints such as melanin index and on the adequacy of safety reporting (PMID 39444151, PMID 29445569).

How is glutathione powder described in the literature?

Trials described oral dosage forms and topical vehicles by dose and duration — for example, 250 mg daily for 12 weeks in the randomised oral trial (PMID 28490897) — without characterising lyophilised powder storage or diluent compatibility. Stability of reduced glutathione in solution is a chemistry question addressed in formulation science rather than in the clinical papers listed below.

Mechanistic and Animal Studies: What Researchers Reported

Outside dermatology, glutathione biology has been examined in models that illustrate why systemic effects are difficult to predict. Researchers investigating glutathione-S-transferase-theta genotypes reported an association analysis between those genotypes and the risk of cyclophosphamide toxicity in dogs, illustrating that glutathione-dependent enzymes participate in drug detoxification and that genotype can track with tolerability (PMID 29984447). A separate canine study evaluated the safety and efficacy of a ribose-cysteine supplement intended to raise erythrocyte glutathione concentration in healthy dogs and reported both the biochemical response and monitoring of tolerability (PMID 34296936).

Glutathione also sits at the centre of ferroptosis regulation. In a rodent model, the study of Beta vulgaris-derived exosome-like nanovesicles reported alleviation of chronic doxorubicin-induced cardiotoxicity through inhibition of ferroptosis, a glutathione-dependent cell-death pathway (PMID 37728183). At the cellular level, researchers reported that glutathione metabolism influenced zinc homeostasis in Saccharomyces cerevisiae, evidence that manipulating this thiol pool has consequences for trace-metal handling (PMID 28505300). These are mechanistic and veterinary findings, not human safety data, and they do not transfer to cosmetic use.

Limitations Researchers Themselves Flagged

• Short follow-up. The principal oral randomised trial ran for 12 weeks (PMID 28490897), leaving longer horizons uncharacterised (PMID 40013212).
• Inconsistent adverse-event capture. The systematic review reported that safety documentation varied widely between studies (PMID 30895708).
• Small samples. The periorbital split-face comparison was an explicitly pilot-scale trial (PMID 36865870).
• Heterogeneous protocols. Reviews of antioxidants in melasma reported wide variation in agents, vehicles and endpoints (PMID 40487500).
• Injectable use unvalidated. Reviews reported that cosmetic intravenous glutathione lacked controlled safety evidence and had drawn regulatory advisories (PMID 27088927, PMID 29445569).

How This Page Relates to the Glutathione Course

This page is limited to the safety and adverse-event literature and to the handling questions that the clinical record leaves unaddressed. For the underlying biochemistry, the melanogenesis pathway, route-by-route study design and how researchers measured pigmentation outcomes, the structured PeptideU glutathione course covers that ground in sequence rather than repeating it here.

References

• Glutathione as a skin whitening agent: Facts, myths, evidence and controversies (Indian Journal of Dermatology, Venereology and Leprology, 2016)
• Glutathione as a skin-lightening agent and in melasma: a systematic review (International Journal of Dermatology, 2025)
• Glutathione and its antiaging and antimelanogenic effects (Clinical, Cosmetic and Investigational Dermatology, 2017)
• Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review (Cureus, 2025)
• Role of Antioxidants in Melasma: A Systematic Review (Indian Journal of Dermatology, 2025)
• Glutathione for skin lightening: a regnant myth or evidence-based verity? (Dermatology Practical & Conceptual, 2018)
• The clinical effect of glutathione on skin color and other related skin conditions: A systematic review (Journal of Cosmetic Dermatology, 2019)
• Efficacy and Safety of Carboxytherapy versus Combined Microneedling with Topical Glutathione in the Treatment of Patients with Periorbital Hyperpigmentation (Indian Journal of Dermatology, 2022)
• Glutathione-S-transferase-theta genotypes and the risk of cyclophosphamide toxicity in dogs (Veterinary and Comparative Oncology, 2018)
• Safety and efficacy of a ribose-cysteine supplement to increase erythrocyte glutathione concentration in healthy dogs (American Journal of Veterinary Research, 2021)
• Beta vulgaris-derived exosome-like nanovesicles alleviate chronic doxorubicin-induced cardiotoxicity by inhibiting ferroptosis (Journal of Biochemical and Molecular Toxicology, 2024)
• Impact of glutathione metabolism on zinc homeostasis in Saccharomyces cerevisiae (FEMS Yeast Research, 2017)